Quick Read – Gilead Sciences (GILD) more than tripled Q1 2026 free cash flow, with its HIV franchise growing 10% and Biktarvy patent protection extended to April 2036, while also returning $419 million to shareholders.
Moderna (MRNA) has surged 63% higher year-to-date but faces 40% revenue collapse in 2025, and is burning cash following a $1.34 billion Q1 GAAP net loss. – Gilead offers retirement-portfolio-quality returns through sustainable free cash flow generation and shareholder capital returns, while Moderna’s bounce reflects a crowded headline trade disconnected from fundamentals of ongoing revenue decline and cash burn. – The analyst who called NVIDIA in 2010 just named his top 10 stocks and Gilead Sciences wasn’t one of them
Get them here FREE. Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look.
The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three years running. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, and management’s own 2026 guidance calls for up to 10% growth off that depressed base. Roughly 80% of Q1 2026 sales came from outside the U.S., and the entire franchise is still effectively a single COVID product.